Summary
Pfizer Inc. (PFE) announced on May 18, 2020, the pricing of a significant public offering of senior notes totaling $4 billion. This offering includes notes maturing in 2025, 2030, 2040, and 2050, with coupon rates ranging from 0.800% to 2.700%. The issuance was conducted under the company's existing shelf registration statement. This debt issuance represents a strategic move by Pfizer to raise substantial capital. Investors should note that the company is securing long-term financing at relatively attractive interest rates. The net proceeds from this offering are expected to be used for general corporate purposes, which could include funding ongoing research and development, potential acquisitions, or managing existing debt obligations. The closing of the offering is anticipated on May 28, 2020.
Key Highlights
- 1Pfizer priced a public offering of $4 billion in aggregate principal amount of senior notes.
- 2The offering includes notes with maturities of 5, 10, 20, and 30 years (2025, 2030, 2040, 2050).
- 3The coupon rates for the notes range from 0.800% to 2.700%.
- 4The issuance was made under the company's existing shelf registration statement filed in February 2018.
- 5The offering was executed with major underwriters including Barclays Capital Inc., Citigroup Global Markets Inc., Deutsche Bank Securities Inc., and J.P. Morgan Securities LLC.
- 6The closing of the offering is expected on May 28, 2020, subject to customary closing conditions.